TIDMAGY
RNS Number : 5901T
Allergy Therapeutics PLC
25 November 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Vesting and Granting of Awards under Long Term Incentive
Plan
Allergy Therapeutics (AIM: AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, announces
that :
Vesting of Award
Performance conditions attaching to provisional awards
("Awards") made pursuant to the Company's Long Term Incentive Plan
("LTIP") for the three years ended 1 November 2021, details of
which were announced on 1 November 2018, have been met in part.
Consequently, on 22 November 2021, Allergy Therapeutics granted
certain of its director's options ("Options") over the Company's
Ordinary Shares of 0.1 pence in replacement for the Awards made
under the LTIP as follows:
Director Percentage of Total number of Exercise Price
Award Vested Ordinary Shares
over which Options
granted
M anuel L lobet 89.3% 803,700 0.1 pence
-------------- ------------------- --------------
Nick Wykeman 89.3% 401,850 0.1 pence
-------------- ------------------- --------------
In accordance with the rules of the LTIP, 50% of these Options
are exercisable immediately and the remaining 50% are subject to a
holding period of three years. The exercise period is ten years
from date of grant.
Granting of Award
Pursuant to the Company's Long Term Incentive Plan ("LTIP") t he
following conditional awards of Ordinary Shares of 0.1 pence each
were made to Executive Directors at a nominal cost of 0.1 pence
each on 22 November 2021 ("New Awards").
Executive Director Number of Conditional shares
awarded (New Awards)
Manuel Llobet 900,000
-----------------------------
Nick Wykeman 450,000
-----------------------------
The New Awards have been granted in accordance with the LTIP
rules and vesting is conditional on the satisfaction of performance
conditions in respect of earnings growth and share price growth
over three years.
Following the above share transactions, the Executive Directors
hold the following:
Director Unvested LTIP Options Interest in Ordinary
Awards Shares
Manuel Llobet 2,700,000 1,676,200 3,325,000
-------------- ---------- ---------------------
Nick Wykeman 1,350,000 838,100 300,000
-------------- ---------- ---------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Manuel Llobet
--------------------- -------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Executive Office and PDMR
--------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--------------------- -------------------------------------------------
b) LEI LEIR97215202003301009534776
--------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description Conditional award of shares and grant of share
of the financial options under the Company's Long Term Incentive
instrument, Plan
type of instrument
--------------------- -------------------------------------------------
b) Identification GB00B02LCQ05
code
--------------------- -------------------------------------------------
c) Nature of the Grant of conditional Awards
transaction
--------------------- -------------------------------------------------
d) Price(s) and Awards Price(s) Volume(s)
volume(s) Options 0.1 pence 803,700
New Awards 0.1 pence 900,000
--------------------- -------------------------------------------------
e) Aggregated
information
1,703,700
0.1 pence
--------------------- -------------------------------------------------
f) Date of the 22 November 2021
transaction
--------------------- -------------------------------------------------
g) Place of the Outside a trading venue
transaction
--------------------- -------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Nick Wykeman
--------------------- -------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Financial Officer and PDMR
--------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--------------------- -------------------------------------------------
b) LEI LEIR97215202003301009534776
--------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description Conditional award of shares and grant of share
of the financial options under the Company's Long Term Incentive
instrument, Plan
type of instrument
--------------------- -------------------------------------------------
b) Identification GB00B02LCQ05
code
--------------------- -------------------------------------------------
c) Nature of the Grant of conditional awards
transaction
--------------------- -------------------------------------------------
d) Price(s) and Awards Price(s) Volume(s)
volume(s) Options 0.1 pence 401,850
New Awards 0.1 pence 450,000
--------------------- -------------------------------------------------
e) Aggregated
information
851,850
0.1 pence
--------------------- -------------------------------------------------
f) Date of the 22 November 2021
transaction
--------------------- -------------------------------------------------
g) Place of the Outside a trading venue
transaction
--------------------- -------------------------------------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines, that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.600 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBABLTMTBTMIB
(END) Dow Jones Newswires
November 25, 2021 04:16 ET (09:16 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
